Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease

Nøjgaard, Camilla; Johansen, Julia S.; Christensen, Erik; Skovgaard, Lene Theil; Price, Paul A.; Becker, Ulrik

doi:10.1016/s0168-8278(03)00184-3

Cited by 134 publications

(110 citation statements)

References 32 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Multiple studies have demonstrated a moderate to strong correlation of serum PIIINP levels with hepatic inflammation and fibrosis stage in patients with CHC. 27 Serum HA is a glycosoaminoglycan that can increase as a result of activated hepatic stellate cell production or reduced he- patic sinusoidal endothelial cell clearance. 16,17,28 Serum TIMP-1 is an inhibitor of circulating matrix metalloproteinases that can increase as fibrogenesis is activated.…”

Section: Discussionmentioning

confidence: 99%

“…YKL-40 also known as human cartilage glycoprotein 39 is a 40-kilodalton glycoprotein that is believed to be involved in tissue remodeling. 27 Serum YKL-40 levels were determined using a commercial ELISA kit (Metra YKL-40, Quidel Corp., San Diego, CA). Undiluted serum samples were run as singlets on microplates and the intra-assay CV was 3.5% and the interassay CV was 6%.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

Fontana¹,

Goodman²,

Dienstag³

et al. 2008

Hepatology

164

117

View full text Add to dashboard Cite

This study determined the utility of a panel of serum fibrosis markers along with routine laboratory tests in estimating the likelihood of histological cirrhosis in a cohort of prior nonresponders with chronic hepatitis C. The relationship between serum markers and quantitative hepatic collagen content was also determined. Liver biopsy samples from 513 subjects enrolled in the HALT-C trial were assigned Ishak fibrosis scores. The collagen content of 386 sirius-red stained, nonfragmented biopsy samples was quantified using computerized morphometry. Serum tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), amino-terminal peptide of type III procollagen (PIIINP), hyaluronic acid (HA), and YKL-40 levels were determined using commercially available assays.Sixty-two percent of patients had noncirrhotic fibrosis (Ishak stage 2-4) whereas 38% had cirrhosis (

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

Fontana¹,

Goodman²,

Dienstag³

et al. 2008

Hepatology

164

117

View full text Add to dashboard Cite

show abstract

“…112 A study of YKL-40 in alcoholic liver disease has suggested that it could function as a marker of clinical outcomes. 113 A further study found it to be more accurate than HA in measuring hepatic fibrosis because of schistosomiasis. 114 …”

Section: Ykl-40mentioning

confidence: 97%

Diagnosis and Quantitation of Fibrosis

2008

View full text Add to dashboard Cite

“…15 Subsequent studies showed that serum YKL-40 decreased in patients with hepatitis C treated with interferon, particularly if the virus is cleared 16 and that among patients with alcoholic liver disease, elevated serum YKL-40 was associated with shortened survival. 17 Similarly, in chronic hepatitis B patients, YKL-40 was reported to be higher in patients with cirrhosis than patients without cirrhosis. 18 Cirrhosis is characterized by increased tissue remodeling of extracellular matrix and accumulation of fibrosis tissue in the liver.…”

Section: Discussionmentioning

confidence: 96%

Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies

et al. 2010

View full text Add to dashboard Cite

Background/Aims: Serum YKL-40 has been linked to several human cancers. We investigated the potential role of serum YKL-40 as a marker of hepatobiliary malignancies. Methods: Archived serum samples of patients undergoing liver transplantation evaluation at the Mayo Clinic Rochester were used to measure YKL-40 levels. Patients were divided into three groups: hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and end-stage liver disease (ESLD) without malignancies. The Model for ESLD (MELD) score was used to quantify the severity of liver disease. Results: The median serum YKL-40 level was highest in the ESLD group at 296 ng/mL, compared to 259 ng/mL in the HCC group and 80 ng/mL in the CCA group (p＜0.01). There was a significant correlation between the MELD score and serum YKL-40 level (r=0.50, p＜0.01). In a multivariate analysis, there was no significant difference in serum YKL-40 level between ESLD and HCC. CCA was associated with lower YKL-40 levels, a finding that was attributable to a lower prevalence of cirrhosis. Conclusions: The serum YKL-40 level has little utility as a cross-sectional screening tool for hepatobiliary malignancies, namely HCC and CCA. The role of YKL-40 as a surveillance marker in the follow-up of individual patients remains to be determined. (Gut Liver 2010;4:537-542)

show abstract

Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease

Cited by 134 publications

References 32 publications

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

Diagnosis and Quantitation of Fibrosis

Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies

Contact Info

Product

Resources

About